Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Final results from ClarIDHy: ivosidenib in IDH1-mutated CCA

Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the final results of the ClarIDHy trial (NCT02989857): a Phase III, randomized, double-blind study of ivosidenib in patients with an isocitrate dehydrogenase 1 mutation (IDH) and previously treated cholangiocarcinoma (CCA). Progression-free survival (PFS) was 1.3 months greater in patients treated with ivosidenib than in the control group and the mean overall survival (OS) rate in the treatment group was more than twice that in the control group. Ivosidenib was generally well tolerated. The results of the ClarIDHy trial may facilitate the approval of ivosidenib for the treatment of mIDH1 CCA. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.